Table Of Content

Breast Cancer Research and Treatment 26: 299-300, 1993. © 1993 Kluwer Academic Publishers. Printed in the Netherlands. Author index, Volume 26 Adkins D S-3 Dunphy F S-3 Kinishita K 67 Allred DC 191, 225 Kitagawa H 67 Amadori D 7 Eckhardt S 41 Kodama H 55 Azavedo E 207 Elledge RM 191, 225 Koenders PG 289 Elliott RL 77 Kornek G 49 Ballerini P 1 Elton RA 89 Krieg SL 191 Bélanger A 253 Encarnacion C 237 Kwasny W 49 Bearman SI S-11, S-19 Benedix MG 191 Ferrari L 1 Labrie F 253 Benraad ThJ 289 Fioravanti L 275 Lehrer SP 175 Benz CC 181 Franco RS 217 Lei Y 163 Berland E 283 Fuqua SAW 117, 191, 225, LeMaistre CF S-1 Bezwoda WR 247 237 Lepage M 253 Bolla M 283 Lewin A 101 Brandt ME 15 Greene GL 191 Lekeso Brufman G 101 LiS 253 Haider K 49 Lower EE 217 Cappelletti V 7, 275 HamertonJ 149 Luce MC 181 Chambaz EM 283 Harada T 55 Chedin M 283 Head JF 77 Marron-Charriere J Chetty U 89 Hennequin E 267 Martelo OJ 217 Ciocca DR 237 Hill BT 23 Martinetti A 1 Clark GM 225, 237 Holm L-E 207 Matthes S S-11 CétéJ 253 Horwitz KB 119 McCoy JL 77 Colonna M 283 McGuire WL 191, Coradini C 275 Ichinose Y 55 zat Correale M 7 Mérand Y 253 Covey DF 15 Jack W 89 Meyers S S-11, S-19 Jardillier J-C 267 Miksicek RJ 163 Daidone MG 7 Jiang S-Y 139 Miller MA 217 Dajee D 247 Jones RB S-11, S-19 Miller WR 89 de Goeij CCJ 289 Jones RJ S-31 Miodini P 275 Delvincourt C 267 Jordan VC 139 MiyazakiI 67 Depisch D 49 Mizukami Y 67 Di Fronzo G 7, 275 Kahan Z 41 Montgomery PA 181 Dolci S 1 Kan N 55 Mor-YosefS 101 Dorembus D 101 Kaufmann M 181 Moriguchi Y 55 Dotzlaw H 149 Kennedy MJ S-31 Murphy LC 149 Duca P 1 Kienhuis CBM 289 Dufton C S-11 Kinami S 67 Nawaz Z 191 300 Author index, Vol. 26 Nilsson B_ 207 Rochefort H 107 Svane G 207 Noguchi M 67 Rostaing-Puissant B 283 Sziics M 41 Nordevang E 207 Ruedl C 275 Takamura H 67 Satoh K 55 Thomas M 67 O’Malley BW 191 Schachter BS 175 Thorpe S 107 Ohgaki K 55 Scheithauer W 49 Oriana S 1 Schenk T 49 Ulrich SJ 95 Osborne CK 237 Schmutzler RK 175 Uziely B 101 SchwarzJ 149 Paradiso A 7 Schweitzer M 95 Velasquez W S-3 Parker CJ 139 Scott GK 181 Veneroni S 7 Parker MG 131 SecretoG | Venturelli E 1 Petruska P S-3 Seymour L 247 Vescernyés M 41 Pirker R 49 Shpall EJ S-11, S-19 Pourny C 267 Shyamala G 95 Wang Y 163 Puett D 15 Silvestrini R 7, 275 Watson DMA 89 Pujol P 225 Sluyser M 289 Whelan RDH 23 Purdy M S-19 Souvignet C 283 Williams SF S-25 Spencer V S-3 Rabin JM 175 Spitzer G S-3 Yamasaki S 55 Ravdin PM 110 Stemmer SM _ S-11, S-19 Riccobon A 7 Sugie T 55 Zimniski SJ 15 Breast Cancer Research and Treatment 26: 301-305, 1993. © 1993 Kluwer Academic Publishers. Printed in the Netherlands. Subject index, Volume 26 4-hydroperoxycyclophosphamide induction of autologous GVHD and antitumor in marrow purging S-19-—S-23 activity S-31-S-40 preparative drug regimens S-3—S-9 adoptive immunotherapy for liver metastases 55-65 cathepsin D alternative splicing as a prognostic factor (discussion) 107-111 and estrogen receptor exon-skipping variants immunohistochemical determination and other 163-174 prognostic factors 7-13 and estrogen receptor variants 149-161 CD34+ selection amifostine accelerated marrow engraftment S-19—S-23 in marrow purging S-19-S-23 chemotherapy aneuploidy dose-intensive (minisymposium) S-1—S-40 see ploidy mdrl gene expression in primary vs. metastatic antiestrogens tumors 267-274 ER point mutation changes structure-function navelbine and mitomycin C in second line relationship 139-147 treatment 49-53 pure steroidal antiestrogens and ER dimerization pharmacokinetics at high doses S-11—S-17 and half-life 131-137 pharmacokinetics in directing drug dosing responses, and estrogen receptor variants 117- S-11-S-17 118 tandem non-cross-resistant combinations see also tamoxifen S-3-S-9 aromatase inhibitors cisplatin 10-propargylestr-4-ene-3,17-dione in rat DMBA BCNU toxicity increase at high doses tumors 15-21 S-11-S-17 autologous bone marrow support in tandem non-cross resistant chemotherapy see bone marrow transplantation combinations S-3—S-9 autologous tumor killing activity cyclic AMP binding proteins in immuno-chemotherapy for liver metastases and prognosis 89-94 55-65 cyclophosphamide in mobilizing peripheral blood progenitor cells B-lymphocyte responses S-25-S-29 to pokeweed mitogen and tumor antigens in in tandem non-cross resistant chemotherapy breast cancer patients 77-88 combinations S-3—S-9 BCNU pharmacokinetic interactions at high doses toxicity increase by high-dose cisplatin S-11-S-17 S-11-S-17 to augment immunotherapy response 55-65 bone marrow transplantation cyclosporine A accelerated engraftment with G-CSF, purging, induction of GVHD and antitumor activity and CD34+ selection S-19-S-23 S-31-S-40 302 Subject index, Vol. 26 cytoxan estrogen receptor (cont.) see cyclophosphamide association with hsp90 levels 95-100 by both ligand binding and immunohisto- Depo-Provera (medroxyprogesterone acetate, MPA) chemistry, in tamoxifen resistance 237-246 controlled release MPA, inhibition of DMBA rat dimerization, half-life, and pure antiestrogens mammary tumors 253-265 131-137 diet exon-skipping variants 163-174 fat intake and mammographic parenchymal genetic polymorphism associated with spon- pattern 207-215 taneous abortion 175-180 DMBA rat mammary tumors loss in drug but not X-ray induced drug resis- regression by a new aromatase inhibitor 15-21 tance 23-39 DNA ploidy non-DNA-binding but immunoreactive variants see ploidy in breast tumors 181-189 dose-intensive therapy point mutation changes antiestrogen structure- in breast cancer (minisymposium) S-1—S-40 function relationship 139-147 drug resistance possible variants in ER+/PgR— breast tumors mdrl gene expression in primary vs. metastatic 191-202 tumors 267-274 truncated variants and alternative splicing 149- X-ray vs. drug induced resistance patterns in 161 MCF-7 cells 23-39 variants in ER-positive and nominally ER- negative cell lines 163-174 EGF receptor estrogen response element downregulation by ER in hormone dependent non-binding ER variants in breast tumors 181- tumors 289-295 189 inverse correlation with EGF-like activity in tumor protease activity mimicking non-DNA- tumor specimens 41-47 binding ER 191-202 endocrine therapy etoposide controlled release MPA, inhibition of DMBA rat in tandem non-cross resistant chemotherapy mammary tumors 253-265 combinations S-3-S-9 regression of rat DMBA tumors by a new aromatase inhibitor 15-21 fat intake resistance and molecular variants of ER and PR and mammographic parenchymal pattern 207- 119-130 ZS tamoxifen resistance vs. true ER status 237-246 endometrium proliferative changes with long-term tamoxifen G-CSF 101-105 accelerated engraftment of hematopoietic pro- epidermal growth factor genitor cells S-19-S-23 see EGF in mobilizing peripheral blood progenitor cells estrogen receptor S-25-S-29 abnormalities in breast cancer (special issue) graft-versus-host disease (GVHD) 117-202 induction and antitumor activity S-31—-S-40 and EGF receptor in hormone dependent vs. growth factors independent tumors 289-295 paracrine interactions between hormone and immunohistochemical localization of dependent and independent cell lines 275- cathepsin D 7-13 281 Subject index, Vol. 26 303 heat shock proteins interferon gamma hsp27 loss in drug but not X-ray induced drug augmentation of GVHD induction and antitumor resistance 23-39 activity S-31-S-40 hsp90 associated with estrogen receptor 95-100 interleukin-2 Helix pomatia lectin (HPA) in immuno-chemotherapy for liver metastases binding as a prognostic factor 67-75 55-65 hematopoietic cell support see bone marrow, peripheral blood stem cells keoxifene (antiestrogen) high-dose chemotherapy ER point mutation changes structure-function in breast cancer (minisymposium) S-1—S-40 relationship 139-147 hormone dependence and EGF receptor levels 289-295 paracrine interactions of dependent and indepen- LINE-1 sequences dent cell lines 275-281 in alternatively spliced ER variants 149-161 hormone resistance lymphocyte responses and molecular variants of ER and PR 119-130 to tumor antigens and general stimulators in ER point mutation changes antiestrogen breast cancer patients 77-88 structure-function relationship 139-147 vs. ER status by both ligand binding and immunohistochemistry 237-246 mammographic parenchymal pattern HPA and dietary fat intake 207-215 see Helix pomatia lectin binding marrow purging 4-hydroperoxycyclophosphamide 4-hydroperoxycyclophosphamide/amifostine in marrow purging S-19-S-23 treatment S-19-S-23 MCF-7 cells ICI 164384 drug vs. X-ray induced drug resistance patterns pure antiestrogens and ER dimerization and half- 23-39 life 131-137 mdrl gene ICI 182780 expression in primary vs. metastatic tumors pure antiestrogens and ER dimerization and half- 267-274 life 131-137 medroxyprogesterone acetate (MPA) IGF-I (insulin-like growth factor I) controlled release MPA, inhibition of DMBA rat and paracrine interactions between hormone mammary tumors 253-265 dependent and independent cell lines 275- microspheres, poly[DL-lactide-co-glycolide] 281 controlled release MPA, inhibition of DMBA rat immuno-chemotherapy mammary tumors 253-265 for liver metastases — immunological mitomycin C parameters 55-65 and navelbine in second line treatment 49-53 immunohistochemistry mitoxantrone quantitative cathepsin D, vs. other prognostic in tandem non-cross resistant chemotherapy factors 7-13 combinations S-3—S-9 immunological parameters mixed lymphocyte tumor reaction in patients with primary breast cancer vs. liver in immuno-chemotherapy for liver metastases metastases 55-65 55-65 lymphocyte responses in breast cancer patients molecular variants 77-88 estrogen receptor (special issue) 117-202 304 Subject index, Vol. 26 multidrug resistance (MDR) progestin resistance mdrl gene expression in primary vs. metastatic and molecular variants of ER and PR 119-130 tumors 267-274 progestin therapy see also drug resistance controlled release MPA, inhibition of DMBA rat mammary tumors 253-265 natural killer cell activity prognostic factors in immuno-chemotherapy for liver metastases cathepsin D, by immunohistochemistry 7-13 55-65 cathepsin D (discussion) 107-111 navelbine cyclic AMP binding proteins 89-94 and mitomycin C in second line treatment 49- EGF receptor vs. EGF-like activity in tumor 53 specimens 41-47 nodal status Helix pomatia \ectin binding 67-75 and Helix pomatia lectin binding 67-75 p53 gene alterations 225-235 phosphotyrosine and tyrosine kinase 217-224 OK-432 (streptococcal immune stimulant) platelet derived growth factor in tumor 247-252 in immuno-chemotherapy for liver metastases tyrosine kinase activity 283-287 55-65 urinary testosterone 1-6 proliferative rate P-glycoprotein by thymidine labelling, and cathepsin D 7-13 see drug resistance protein tyrosine kinase p53 see tyrosine kinase gene alterations and prognosis 225-235 pS2 paracrine interactions loss in drug-induced but not X-ray-induced drug co-culture of hormone dependent and indepen- resistance 23-39 dent cell lines 275-281 pulmonary toxicity peripheral blood lymphocytes and high-dose drug interactions S-11—S-17 in immuno-chemotherapy for liver metastases purging 55-65 4-hydroperoxycyclophosphamide/amifostine peripheral blood progenitor cells treatment of marrow S-19-S-23 in reconstitution after high-dose chemotherapy S-25-S-29 recurrence pharmacokinetics urinary testosterone as a marker 1-6 high-dose interactions of cisplatin and BCNU recurrence risk S-11-S-17 see prognostic factors phosphotyrosine RNA splicing elevation in breast cancer, by immunohisto- and estrogen receptor variants 117-118 chemistry 217-224 RU 39,411 (antiestrogen) platelet derived growth factor (PDGF) ER point mutation changes structure-function in tumor tissue, vs. prognosis 247-252 relationship 139-147 ploidy and Helix pomatia lectin binding, nodal status 67-75 single-stranded conformation polymorphism analysis progesterone receptor p53 gene alterations and prognosis 225-235 and hsp90 levels 95-100 splicing variants isoforms, antagonists, and function 127-128 estrogen receptor and LINE-1 sequences 149- status in hormone resistant tumors 237-246 161 Subject index, Vol. 26 spontaneous abortion thiotepa association with estrogen receptor genetic in tandem non-cross resistant chemotherapy polymorphism 175-180 combinations S-3—S-9 stem cell transplantation toxicity preparative drug regimens S-3-—S-9 and pharmacokinetics at high doses S-11—S-17 stem cells tumor antigens accelerated engraftment by CD34+ selection T- and B-lymphocyte responses in breast cancer S-19-S-23 patients 77-88 tyrosine kinase T-cell growth factor activity and prognosis 283-287 in immuno-chemotherapy for liver metastases elevation in breast cancer 217-224 55-65 T-lymphocyte responses ultrasound to phytohemagglutinin and tumor antigens in in evaluation of endometrial changes with long- breast cancer patients 77-88 term tamoxifen 101-105 tamoxifen urinary markers and endometrial proliferative changes 101-105 testosterone and recurrence risk 1-6 ER point mutation changes structure-function relationship 139-147 VP-16 resistance and molecular variants of ER and PR see etoposide 119-130 resistance and true ER status 237-246 testosterone WR-2721 prognostic factor in urine 1-6 see amifostine TGFa (transforming growth factor alpha) and paracrine interactions between hormone ZR-75-1 cells dependent and independent cell lines 275- drug vs. X-ray induced drug resistance patterns 281 23-39